Shanghai Junshi Biosciences Co., Ltd.
http://junshipharma.com/en/Index.html
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Shanghai Junshi Biosciences Co., Ltd.
Shionogi Files Antiviral NDA In China, Eyes Wider Use
Undeterred by recent home turf setback, Japanese drug maker Shionogi rides a China’s policy tailwind and bets on Chinese approval for its antiviral COVID drug.
BeiGene Latest Chinese Biotech To Double Down On mRNA For Cancer
Chinese biotechs have reached deals for cancer therapies to explore the novel uses of messenger RNA technology beyond COVID-19 vaccines, as the mRNA COVID-19 vaccine fame starts fading.
CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: GSK boosts vaccine presence via M&A; US PBM formulary exclusions on the rise; ASCO data portend battle for bispecifics in lymphoma; mixed ASCO data for Cabometyx combos; and Junshi’s oral COVID-19 antiviral shows promise although questions remain.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Junshi Biosciences